Treloars at 00:45, 24 April 2020

2020-04-24T00:45:51Z

← Older revision		Revision as of 00:45, 24 April 2020
Line 30:		Line 30:
	\|-		\|-
	! '''BLACK BOX WARNING'''		! '''BLACK BOX WARNING'''
	The IV (perenteral) administration of ~~[[Antiemetics\|~~PHENERGAN (PROMETHAZINE)]] has a '''RELATIVE CONTRAINDICATION''' in children under 2 years of age. The provider must weigh the risk vs. benefit of ~~[[Antiemetics\|~~PHENERGAN (PROMETHAZINE)]] administration based on the patient's condition.		The IV (perenteral) administration of PHENERGAN (PROMETHAZINE) has a '''RELATIVE CONTRAINDICATION''' in children under 2 years of age. The provider must weigh the risk vs. benefit of PHENERGAN (PROMETHAZINE) administration based on the patient's condition.
	\|}		\|}

	[[Category:Medication Guidelines\|Promethazine]]		[[Category:Medication Guidelines\|Promethazine]]

Treloars: Created page with "==Section 8 - MEDICATION GUIDELINES== ===ANTIEMETICS=== ====Promethazine (PHENERGAN) / Antiemetic==== '''DESCRIPTION:''' * Blocks cholinergic receptors in the vomiting center..."

2020-04-24T00:38:37Z

Created page with "==Section 8 - MEDICATION GUIDELINES== ===ANTIEMETICS=== ====Promethazine (PHENERGAN) / Antiemetic==== '''DESCRIPTION:''' * Blocks cholinergic receptors in the vomiting center..."

New page

==Section 8 - MEDICATION GUIDELINES==
===ANTIEMETICS===

====Promethazine (PHENERGAN) / Antiemetic====
'''DESCRIPTION:'''
* Blocks cholinergic receptors in the vomiting center, which may mediate nausea and vomiting; competes with histamine for the H1 receptor site.
'''ACTION:'''
* Blocks the effects of the hormone serotonin at the 5-HT3 -receptor sites (located in the vagal nerve terminals) that cause vomiting.
* Half-life 3.5 - 5.5 hr
'''INDICATIONS:'''
* Severe, persistent vomiting.
'''CONTRAINDICATIONS:'''
* Coma, CNS depression, seizures, known hypersensitivity to drug
'''PRECAUTIONS:'''
* Get as complete a history as possible before administering.
* Using with epinephrine may result in further hypotension.
* Using with barbiturates, tranquilizers, or alcohol may further CNS depression
* '''''FDA MANDATED BLACK BOX WARNING: If this medication is administered incorrectly it can cause severe skin damage up to and including gangrene. This damage may lead to amputation of the affected limb.'''''
'''DOSAGE:'''
* Currently supplied in 25 mg/ml vial
* Adult (>13 y/o): 12.5 mg slow IVP, or IM.
** Dilution is not necessary when given IM
** IV site must be checked for patency before infusing the medication – document patent flow of the IV site on the patient care report
** '''MUST be diluted in a minimum of 10 ml of normal saline when given IV'''
** '''MUST be given through an IV line actively infusing fluids'''
* Pediatric: .25-1mg/kg slow IVP, or IM.
** Dilution is required as noted above.
** The maximum single dose to be given must not exceed 12.5 mg
{| class="wikitable"
|-
! '''BLACK BOX WARNING'''
The IV (perenteral) administration of [[Antiemetics|PHENERGAN (PROMETHAZINE)]] has a '''RELATIVE CONTRAINDICATION''' in children under 2 years of age. The provider must weigh the risk vs. benefit of [[Antiemetics|PHENERGAN (PROMETHAZINE)]] administration based on the patient's condition.
|}

[[Category:Medication Guidelines|Promethazine]]

Promethazine - Revision history

Treloars at 00:45, 24 April 2020

Treloars: Created page with "==Section 8 - MEDICATION GUIDELINES== ===ANTIEMETICS=== ====Promethazine (PHENERGAN) / Antiemetic==== '''DESCRIPTION:''' * Blocks cholinergic receptors in the vomiting center..."